MedTrace Logo

Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy

NCT00695318 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2015-05-29

Study results available
· View outcomes & findings →

Summary

This study will compare the safety and efficacy of Medidur FA treatment in one eye to the sham-treated fellow eye of subjects with geographic atrophy secondary to AMD.

Conditions

  • Age-Related Macular Degeneration

Interventions

DRUG

Fluocinolone Acetonide

0.2 µg/Day in study eye + Sham in fellow eye

DRUG

Fluocinolone Acetonide

0.5 µg/Day in study eye +Sham in fellow eye

Sponsors & Collaborators

  • Alimera Sciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2013-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00695318 on ClinicalTrials.gov